EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

Mohit Mathur, Jonathan Barratt, Bobby Chacko, Tak Mao Chan, Laura Kooienga, Kook-Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J G Pereira und 1 weitere

New England Journal of Medicine · 04.01.2024 · 390 (1) · 20-31

DOI: 10.1056/nejmoa2305635 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.01.2024. Verfasst von Mohit Mathur und 12 weiteren Autor:innen. Beteiligte Einrichtung: From Visterra, Waltham, MA (M.M., J.Y., B.J.G.P.); John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom (J.B.); Nephrology an…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Antibodies, Monoclonal, Humanized, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit wurde bisher 236-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: DBT-Wellcome Trust India Alliance, Visterra, Inc., a member of the Otsuka family of companies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAntibodies, Monoclonal, HumanizedTumor Necrosis Factor Ligand Superfamily Member 13AdultHumansAdministration, IntravenousCreatinineDouble-Blind MethodGlomerular Filtration RateProteinuriaImmunoglobulin G

Substanzen

CreatinineAntibodies, Monoclonal, HumanizedTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13Immunoglobulin G

Autor:innen und Institutionen

  • From Visterra, Waltham, MA (M.M., J.Y., B.J.G.P.); John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom (J.B.); Nephrology and Transplantation, John Hunter Hospital and University of Newcastle, N…

Förderung

  • DBT-Wellcome Trust India Alliance
  • Visterra, Inc., a member of the Otsuka family of companies

Zitieren

APA

Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K. H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., Xia, J., Pereira, B. J. G., & ENVISION Trial Investigators Group (2024). A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. New England Journal of Medicine, 390(1), 20-31. https://doi.org/10.1056/nejmoa2305635

Vancouver

Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. New England Journal of Medicine. 2024;390(1):20-31. doi:10.1056/nejmoa2305635

BibTeX
@article{Mathur2024,
  author = {Mathur, Mohit and Barratt, Jonathan and Chacko, Bobby and Chan, Tak Mao and Kooienga, Laura and Oh, Kook-Hwan and Sahay, Manisha and Suzuki, Yusuke and Wong, Muh Geot and Yarbrough, Jill and Xia, Jing and Pereira, Brian J G and ENVISION Trial Investigators Group, ENVISION Trial Investigators Group},
  title = {A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {1},
  pages = {20--31},
  doi = {10.1056/nejmoa2305635}
}
Kostenlos starten →